Using generative biology and chemistry, we are revolutionizing the speed and accuracy of how medicine is created.
Our HyperloopTM Platform combines deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure to create candidate-ready compounds with unprecedented speed.
Our HyperloopTM Platform unites novel structure-based drug discovery with AI-driven computational approaches and experimental readouts to discover and validate small molecule therapeutics.
With an initial focus on GPCRs, our pipeline combines scientific ingenuity with patient-focused precision, developing next-generation treatments for cardiometabolic diseases.